Leukotriene Receptor

Leukotriene Receptor Related Products (110):

By Effects:	Control (1) Inhibitors (34) Agonists (6) Antagonists (52) Activators (2)

Cat. No.	Product Name	Effect	Purity

HY-14166

MK-886	Inhibitor	99.77%
MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC₅₀ of 30 nM) and leukotriene biosynthesis (IC₅₀s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis.

HY-B0174

Olsalazine Disodium		99.89%
Olsalazine Disodium is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.

HY-B0174A

Olsalazine	Inhibitor	99.83%
Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC₅₀ value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity.

HY-76511

Verlukast		98.61%
Verlukast is a potent, selective, and orally active antagonist of leukotriene receptor. Verlukast has the potential for the research of asthma.

HY-105484

U-75302	Inhibitor	≥99.0%
U-75302 is a potent inhibitor of leukotriene B4. U-75302 is a pyridine analogue. U-75302 has the potential for the research of inflammatory diseases.

HY-P3318

Boc-Phe-Leu-Phe-Leu-Phe	Antagonist	98.03%
Boc-Phe-Leu-Phe-Leu-Phe, a chemotactic peptide antagonist, abolishes the FMLP-induced release of peptide leukotrienes.

HY-N15230

Torososide B
Torososide B is an antiallergic compound that inhibits calcium ionophore A-induced leukotriene release from rat peritoneal mast cells.

HY-13315BR

Montelukast (dicyclohexylamine) (Standard)	Antagonist
Montelukast (dicyclohexylamine) (Standard) is the analytical standard of Montelukast (dicyclohexylamine). This product is intended for research and analytical applications. Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research.

HY-108396

γ-Linolenic acid ethyl ester	Antagonist	99.14%
γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B₄ receptor 4 (LTB₄) antagonist.

HY-108693

β-Tocotrienol		98.89%
β-Tocotrienol is one form of vitamin E. β-Tocotrienol is a less potent antioxidant than α-tocotrienol.

HY-111212

Tomelukast	Antagonist	≥99.0%
Tomelukast (LY171883) is an orally active leukotriene D₄ and E₄ antagonist. Tomelukast can be used for the research of asthma.

HY-106929

Moxilubant	Antagonist	99.83%
Moxilubant (CGS-25019C;LTB-019) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2–4 nM. Moxilubant can be used for cancer research.

HY-101676

RG-12525	Antagonist	98.31%
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC₅₀s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC₅₀ of appr 60 nM and a potent inhibitor of CYP3A4, with a K_i value of 0.5 µM.

HY-156978

Ritolukast	Antagonist	99.92%
Ritolukast (Wy-48252) is an orally active aerosol leukotriene (LTD₄/E₄) receptor antagonist. Ritolukast can be used to inhibit the bronchoconstriction caused by aerosol LTD₄ in guinea pigs, with an ID₅₀ of 0.5mg/kg.

HY-13315S1

Montelukast-d₆ sodium	Antagonist
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

HY-107608S

Leukotriene B4-d₄
Leukotriene B4-d₄ is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2][3].

HY-107610

SR2640 hydrochloride	Antagonist	99.60%
SR2640 (hydrochloride) is a potent and selective competitive leukotriene D4/leukotriene E4 antagonist. SR2640 can be used for researching the role of leukotrienes in human asthma.

HY-101438

Darbufelone	Inhibitor	≥98.0%
Darbufelone is a dual inhibitor of cellular PGF_2α and LTB₄ production. Darbufelone potently inhibits PGHS-2 (IC₅₀= 0.19 μM) but is much less potent with PGHS-1 (IC₅₀=20 μM).

HY-149589

11(Z),14(Z)-Eicosadienoic acid	Inhibitor	≥98.0%
11(Z),14(Z)-Eicosadienoic acid is a unsaturated fattly acid that inhibits [³H] leukotriene B₄ (LTB₄) binding to pig neutrophil membranes with a K_i of 3 μM. 11(Z),14(Z)-Eicosadienoic acid has inflammatory activities.

HY-145234

GPBAR1-IN-3	Antagonist
GPBAR1-IN-3 (Compound 14) is a selective GPBAR1 agonist (EC₅₀=0.17 μM) and a CysLT₁R antagonist.

Name
Email *

	Sorry, but the email address you supplied was invalid.